Compare AEVA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | NBTX |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | France |
| Employees | 239 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2018 |
| Metric | AEVA | NBTX |
|---|---|---|
| Price | $24.84 | $41.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $26.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 2.1M | 74.2K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $85.37 | $58.17 |
| Revenue Next Year | $132.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $3.86 |
| 52 Week High | $38.79 | $57.14 |
| Indicator | AEVA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 49.82 |
| Support Level | $12.37 | $28.35 |
| Resistance Level | N/A | $41.89 |
| Average True Range (ATR) | 2.45 | 3.80 |
| MACD | 0.60 | -0.88 |
| Stochastic Oscillator | 94.44 | 33.03 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.